Erythema multiforme - Eritèm Multiforme
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Erythema multiforme minor ― Remake byen ke sant blesi yo ka blanchi.
Urtikarya ka konsidere tou kòm yon dyagnostik diferans.
References
Erythema multiforme (EM) se yon kondisyon kote tach diferan ki tankou sib parèt sou po a ak manbràn mikez akòz reyaksyon iminitè. Malgre ke souvan deklanche pa enfeksyon viral, espesyalman viris èpès senp (HSV) , oswa sèten medikaman, kòz la rete enkoni nan anpil ka. Trete EM egi konsantre sou soulaje sentòm yo lè l sèvi avèk krèm ki gen estewoyid oswa antihistamin. Jere EM renouvlab pi efikas lè yo adapte pou chak pasyan. Apwòch inisyal enplike tou de tretman oral ak aktualite. Men sa yo enkli kortikoterapi ak medikaman antiviral. Tretman aktualite konpoze de krèm esteroyid fò ak solisyon pou manbràn mikez ki afekte yo. Pou pasyan ki pa reponn a antiviral, opsyon dezyèm liy yo enkli dwòg iminitè, antibyotik, anthelmintics, ak antimalaryal.
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Nan anpil ka, modere erythema multiforme disparèt poukont li nan 2 a 4 semèn. Sendwòm Stevens-Johnson, yon kondisyon grav ki afekte manbràn mikez yo, ka dire jiska 6 semèn. Estewoyid yo pa tipikman rekòmande pou ka grav. Si wi ou non estewoyid yo ta dwe itilize pou eritem miltifòm grav se ensèten paske pa gen okenn rezilta klè nan etid owaza ki endike ki timoun ki ta benefisye de tretman sa a.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
Nou prezante yon ka erythema multiforme (EM) oral ki te koze pa TMP/SMX , ki montre tipik maladi ilsè oral ak lèv san blesi po. Sa a souliye bezwen pou diferansye li de lòt maladi ilsè oral. Pasyan an te resevwa tretman sentòm ak tablèt prednisolòn, ki mennen nan amelyorasyon apre yo fin sispann terapi TMP / SMX.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
Erythema multiforme se yon reyaksyon ki enplike po a epi pafwa mukoza a, deklanche pa sistèm iminitè a. Tipikman, li manifeste kòm blesi tankou sib, ki ka parèt izole, repete, oswa pèsiste. Blesi sa yo anjeneral simetrik afekte ekstremite yo, patikilyèman sifas ekstèn yo. Kòz prensipal yo enkli enfeksyon tankou viris èpès senp ak Mycoplasma pneumoniae, osi byen ke sèten medikaman, vaksinasyon, ak maladi otoiminitè. Distenksyon erythema multiforme ak urtikè depann sou dire blesi yo; erythema multiforme blesi yo rete fiks pou omwen sèt jou, pandan y ap blesi urtikè souvan disparèt nan yon jou. Malgre ke menm jan an, li enpòtan anpil pou diferansye erythema multiforme ak sendwòm Stevens-Johnson ki pi grav, ki tipikman prezante makil eritematoz oswa purpurik toupatou ak ti anpoul. Jere erythema multiforme enplike soulajman sentòm ak estewoyid aktualite oswa antihistamin ak adrese kòz ki kache a. Pou ka frekan ki asosye ak viris èpès senp, yo rekòmande terapi antiviral pwofilaktik. Patisipasyon mikoz grav ka bezwen entène lopital pou likid nan venn ak ranplasman elektwolit.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Kondisyon an varye soti nan yon gratèl ki pa grav, ki limite pwòp tèt ou nan yon fòm grav, ki menase lavi ke yo rekonèt kòm eritem miltifòm pi gwo ki enplike tou manbràn mikez. Envazyon nan manbràn mikez la oswa prezans nan bullaes se siy enpòtan nan severite.
- Erythema multiforme minor: sib tipik oswa leve soti vivan, papul edem yo distribiye akrèlman
Fòm nan twò grav anjeneral prezante ak yon ti kras grate (men demanjezon ka trè grav), tach woz-wouj, ranje simetrik epi kòmanse sou ekstremite yo. Rezolisyon gratèl la nan 7-10 jou se nòmal nan fòm sa a nan maladi a.
- Erythema multiforme major: sib tipik oswa leve, papul edematoz distribye akrèlman ak patisipasyon nan youn oswa plis manbràn mikez. Detachman epidèm enplike mwens pase 10% nan sifas kò total.
○ Tretman - Medikaman OTC
Si li akonpaye pa yon lafyèv (k ap monte tanperati kò), li rekòmande pou vizite lopital la pi vit posib.
Dwòg yo sispèk yo ta dwe sispann. (egzanp antibyotik, dwòg anti-enflamatwa ki pa esteroyid)
Antihistamin oral tankou cetirizine ak loratadine pou demanjezon.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]